Summary
Signal counts
Assets tracked: 4
Watchlist assets: 3
Registry stop assets: 1
Sponsor overview
Novartis Pharmaceuticals
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT01402401 | https://clinicaltrials.gov/study/NCT00088595 | https://clinicaltrials.gov/study/NCT00171834 | https://clinicaltrials.gov/study/NCT01147822 | https://clinicaltrials.gov/study/NCT02383251 | https://clinicaltrials.gov/study/NCT01280201
Assets
Linked programs
- AUY922: Registry Stop Signal (4/5)
- Pasireotide (SOM230): Low Signal (1/5)
- Patupilone: Watchlist Signal (2/5)
- Pazopanib: Operational Burden Signal (4/5)